Clinical, Biochemical and Genetic Analyses in Two Korean Patients with Medium-chain Acyl-CoA Dehydrogenase Deficiency by Woo, Hye In et al.
54     www.kjlm.org
Clinical, Biochemical and Genetic Analyses in Two Korean Patients with 
Medium-chain Acyl-CoA Dehydrogenase Deficiency
Hye In Woo, M.D.
1, Hyung-Doo Park, M.D.
1, Yong-Wha Lee, M.D.
2, Dong Hwan Lee, M.D.
3, Chang-Seok Ki, M.D.
1, 
Soo-Youn Lee, M.D.
1, and Jong-Won Kim, M.D.
1
Department of Laboratory Medicine & Genetics
1, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul; Department of 
Laboratory Medicine & Genetics
2, Soonchunhyang University Bucheon Hospital, Soonchunhyang University College of Medicine, Bucheon; 
Department of Pediatrics
3, College of Medicine, Soonchunhyang University, Seoul, Korea
Medium-chain acyl-CoA dehydrogenase deficiency (MCADD) is an autosomal recessive hereditary metabolic disorder of mito-
chondrial fatty acid β-oxidation. It is characterized by hypoketotic hypoglycemia, hyperammonemia, seizure, coma, and sudden 
infant death syndrome-like illness. The most frequently isolated mutation in the acyl-CoA dehydrogenase, medium-chain (ACADM) 
gene of Caucasian patients with MCADD is c.985A>G, but ethnic variations exist in the frequency of this mutation. Here, we de-
scribe 2 Korean pediatric cases of MCADD, which was detected during newborn screening by tandem mass spectrometry and 
confirmed by molecular analysis. The levels of medium-chain acylcarnitines, including octanoylcarnitine (C8), hexanoylcarnitine 
(C6), and decanoylcarnitine (C10), were typically elevated. Molecular studies revealed that Patient 1 was a compound heterozygote 
for c.449_452delCTGA (p.Thr150ArgfsX4) and c.461T>G (p.L154W) mutations, and Patient 2 was a compound heterozygote for 
c.449_452delCTGA (p.Thr150ArgfsX4) and c.1189T>A (p.Y397N) mutations. We detected asymptomatic patients with MCADD by 
using a newborn screening test and confirmed it by ACADM mutation analysis. This report presents evidence of the biochemical 
and molecular features of MCADD in Korean patients and, to the best of our knowledge, this is the first report of the c.461T>G mu-
tation in the ACADM gene.
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Medium-chain acyl-CoA dehydrogenase deficiency (MC-
ADD; OMIM 607008) is an autosomal recessive metabolic 
disorder of mitochondrial fatty acid β-oxidation. Medium-
chain acyl-CoA dehydrogenase (MCAD) is a homotetramer 
and shows its highest activity with octanoyl-CoA. Clinical 
symptoms are variable, including hypoketotic hypoglyce-
mia, hyperammonemia, gastritis, lethargy, seizure, coma, 
and sudden infant death syndrome (SIDS)-like illness. In 
about 20% of the patients, sudden death occurs at the first 
presentation of the disease [1]. Other affected individuals 
may remain without any symptoms for several years [2, 3]. 
The duration of the onset of the symptoms can range be-
tween 2 days to 6.5 yr, and the symptoms are triggered by 
catabolic stresses such as infection and prolonged fasting 
[1]. To prevent catabolic stress, patients are made to con-
sume a carbohydrate-rich diet and carnitine supplements 
and prevented from fasting.
MCADD is the most frequently diagnosed clinical defect 
of fatty acid metabolism in Caucasians. The frequency of 
the disease ranges from 1:10,000 to 1:30,000 in the United 
States, and it is detected during newborn screening using 
tandem mass spectrometry [2, 4-6]. However, this disorder Woo HI, et al.  •  Two Korean Cases with MCAD Deficiency
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is relatively rare in Asian populations. Although the frequency 
of MCADD detection has increased after the introduction 
of neonatal newborn screening with tandem mass spec-
trometry, including acylcarnitine analysis, and with the in-
crease of awareness of the disorder, it is still rare in Asians. 
The incidence of MCADD is 1:51,000 in the Japanese popu-
lation, and there were no cases of the disorder among the 
79,179 newborns screened in Korea [7, 8]. To date, 1 Ko-
rean and 11 Japanese patients have been confirmed to be 
positive for MCADD by molecular analysis [9-12].
The human ACADM gene is located on chromosome 
1p31 and spans 44 kb. It contains 12 exons encoding a ma-
ture protein of 396 amino acids (43.6 kDa) [13]. The muta-
tion frequency in the ACADM gene shows ethnic variation. 
In Caucasian patients with MCADD, a common c.985A>G 
mutation was identified in about 80–90% of the mutant al-
leles [2, 14]. However, the results of 2 previous reports indi-
cate that c.449_452delCTGA is the most common disease-
causing ACADM mutation identified in Asians [9, 10, 12]. 
In this report, we describe 2 Korean pediatric patients with 
MCADD that was detected during newborn screening tests 
by tandem mass spectrometry. Molecular studies revealed 2 




A female patient was born at a gestational age of 37 weeks 
and 5 days by spontaneous vaginal delivery, and her weight 
at birth was 2.86 kg. She did not have any clinical manifes-
tations of metabolic disorders. However, MCADD was sus-
pected on the basis of the results of newborn screening tests, 
and the patient was referred to our hospital.
On postnatal day 23, plasma amino acid analysis showed 
an elevated methionine level of 77 μmol/L (reference inter-
val (RI), 22.9–41.7 μmol/L), elevated tyrosine level of 217 
μmol/L (RI, 49.1–88.9 μmol/L), and elevated ornithine level 
of 227 μmol/L (RI, 39.4–130.6 μmol/L). Plasma acylcarni-
tine profile revealed an accumulation octanoylcarnitine level 
of 2.19 μmol/L (RI, ≤0.5 μmol/L) and hexanoylcarnitine 
level of 0.78 μmol/L (RI, ≤0.44 μmol/L), and these findings 
are considered to be typical of MCADD (Table 1). The lev-
els of total and free carnitines were within the normal range. 
Hexanoylglycine, suberylglycine, and 5-hydroxycaproic 
acid were detected in urine organic acid analysis. Other lab-
oratory investigations showed a normal total bilirubin level 
of 147.06 μmol/L (RI, 17.1–205.2 μmol/L) and AST level of 
46 U/L (RI, 16–74 U/L), and slightly elevated alkaline phos-
phatase (ALP) level of 335 U/L (RI, 40–300 U/L). Ammo-
nia (75.22 μmol/L; RI, 14.68–38.17 μmol/L) and lactate lev-
els (4.6 mmol/L; RI, 0.6–3.2 mmol/L) were elevated. The 
patient was diagnosed with MCADD on the basis of the 
above findings and was administered carnitine supplements 
with frequent food intake. 
Two months later, the plasma amino acid levels had nor-
malized; however the octanoylcarnitine level remained ele-
vated at 2.59 μmol/L on acylcarnitine analysis. Urine organic 
Table 1. Clinical, biochemical and molecular features of Korean patients with MCADD
Patient 1* Patient 2* Patient 3
†
Age at sampling 23 days 14 days ND
Sex F M M
Body weight (g) 2,860 3,740 ND
Clinical presentation Asymptomatic Asymptomatic Dehydration, acidosis, hypoglycemia, tremor
Plasma acylcarnitines (μmol/L)
   C6
‡ 0.78 1.28 0.33
   C8
‡ 2.19 7.51 4.58
   C10
‡ Not elevated 0.62 0.41
ACADM genotype (allele1/allele2)
   Location Exon 6/Exon 6 Exon 6/Exon 11 Exon 6/Exon 9
   cDNA c.449_452delCTGA/c.461T>G c.449_452delCTGA/c.1189T>A c.449_452delCTGA/c.843A>T
   Precursor protein
§ p.Thr150fs/p.L154W p.Thr150fs/p.Y397N p.Thr150fs/p.R281S
   Mature protein
§ p.Thr125fs/p.L129W p.Thr125fs/p.Y372N p.Thr125fs/p.R256S
   Clinical outcome Well, 12 months Well, 5 months Well, 5 months
*Identified in the present report; 
†Ref. [10]; 
‡C6, hexanoylcarnitine; C8, octanoylcarnitine; C10, decanoylcarnitine; 
§The cDNA of the ACADM gene encodes the entire protein of 
421-amino acid including a 25-amino acid leader and a 396-amino acid mature polypeptide [13].
Abbreviations: MCADD, medium-chain acyl-CoA dehydrogenase deficiency; ND, not determined; ACADM, acyl-CoA dehydrogenase, medium-chain.56     www.kjlm.org
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acid analysis showed an elevated suberylglycine level of 3.52 
mmol/molCr (RI, not detected), suberic acid level of 12.82 
mmol/molCr (RI, <10.1 mmol/molCr), and sebacic acid 
level of 7.66 mmol/molCr (RI, <1.4 mmol/molCr); these 
analyses also showed peaks for octanedioic acid and de-
cenedioic acid. Liver function tests revealed normal total 
bilirubin and AST levels; however, ALP, ammonia, and lac-
tate levels remained as high as before. The pediatric patient 
has been growing normally and has been continuously fol-
lowed without apparent problems.
2. Patient 2
A male patient was born at a gestational age of 39 weeks 
and 5 days by spontaneous vaginal delivery, and his weight 
at birth was 3.74 kg. There was no clinical evidence of meta-
bolic disorder at the time of birth. However, MCADD was 
suspected on the basis of the results of newborn screening 
with tandem mass spectrometry, and the patient was referred 
to our hospital at 10 days of age.
Amino acid analysis showed that hydroxyproline (99.4 
μmol/L; RI, 0–91 μmol/L) and proline (769.9 μmol/L; RI, 
110–417 μmol/L) levels were slightly elevated. Plasma acyl-
carnitine analysis showed an elevated octanoylcarnitine level 
of 7.51 μmol/L, hexanoylcarnitine level of 1.28 μmol/L, and 
decanoylcarnitine level of 0.62 μmol/L (RI, ≤0.51 μmol/L) 
at 14 days of age. Urine organic acid analysis revealed eleva-
tions in hexanoylglycine (3.30 mmol/molCr; RI, not de-
tected) and suberylglycine (2.46 mmol/molCr) levels. Other 
abnormal laboratory findings included elevated ALP levels 
(532 U/L; RI, 40–300 U/L), hyperphosphatasemia (2.65 
mmol/L; RI, 1.55–2.61 mmol/L), hyperammonemia (74.05 
μmol/L), and a lactate level (3.2 mmol/L) that was the up-
per limit of the normal value. The patient was suspected to 
have MCADD on the basis of these biochemical findings.
At 17 days of age, the patient developed fever, cough, rhi-
norrhea, and dyspnea due to a respiratory syncytial virus 
infection and received conservative treatment. He recov-
ered fully and was discharged.
At 44 days of age, plasma amino acid analysis revealed 
non-specific elevations in the levels of glutamic acid, cys-
tine, and proline. Plasma acylcarnitine analysis showed ab-
normalities when compared with the control profiles, with 
elevations in the levels of octanoylcarnitine (1.66 μmol/L) 
and hexanoylcarnitine (0.53 μmol/L) and normal levels of 
total and free carnitine levels. Urine hexanoylglycine, su-
berylglycine, suberic acid, and sebacic acid levels were ele-
vated at 3.05 mmol/molCr, 2.33 mmol/molCr, 16.00 mmol/
molCr, and 5.36 mmol/molCr, respectively, and peaks of 
5-hydroxycarproic acid, 7-hydroxyoctanoic acid, cis-4-oc-
tenedioic acid, and decenedioic acid were observed in urine 
organic acid analysis. The results of liver function tests were 
almost normal, but hyperammonemia (58.25 μmol/L) and 
lactic acidosis (3.9 mmol/L) persisted.
At 56 days of age, the plasma octanoylcarnitine level still 
remained elevated (1.52 μmol/L) and the levels of hexanoyl-
glycine and suberylglycine were observed to be elevated at 
1.38 mmol/molCr and 1.25 mmol/molCr, respectively, in 
urine organic acid analysis. The pediatric patient has been 
growing normally so far and is under outpatient follow-up.
3. Mutation analysis
Genomic DNA was extracted from the peripheral blood 
leukocytes of both patients and the parents of Patient 1 by 
using the Wizard Genomic DNA Purification Kit according 
to the manufacturer’s instructions (Promega, Madison, WI, 
USA). All exons of the ACADM gene were amplified by PCR 
on a thermal cycler (Applied Biosystems, Foster City, CA, 
USA) with primer pairs designed by the authors. Direct se-
quencing was performed with the BigDye Terminator Cycle 
Sequencing Ready Reaction kit on an ABI Prism 3130 Ge-
netic Analyzer (Applied Biosystems). The sequences were 
analyzed using the Sequencher program (Gene Codes Corp., 
Ann Arbor, MI, USA) and were compared to the reference 
sequences. The numbering of nucleotide positions was done 
according to the ACADM cDNA sequence, and the Gen-
Bank accession number was NM 000016.4. Sequence varia-
tion was described according to the recommendations of 
the Human Genome Variation Society (http://www.hgvs.
org/mutnomen).
In Patient 1, sequence analysis of the ACADM gene re-
vealed a known mutation, c.449_452delCTGA (p.Thr150-
ArgfsX4), in exon 6 and a previously unrecognized muta-
tion in the same exon, a T to G transversion at position 461 
that would alter a leucine to tryptophan at amino acid posi-
tion 154 (p.L154W) (Fig. 1). Sequencing analysis of Patient 
1’s parents showed that the mother was heterozygous for 
the c.449_452delCTGA mutation, and the father was het-
erozygous for the c.461T>G mutation. A control study con-
ducted using the exon 6 targeted sequencing analyses in 340 
alleles of 170 healthy subjects did not reveal any carriers of 
the c.461T>G mutation. The novel mutation is associated 
with major amino acid substitutions, and this mutation is 
likely to be the cause of the disorder. Using the SWISS-MO-
DEL and Swiss-Pdb Viewer, the protein structure was ana-
lyzed: the novel mutation was predicted to cause no signifi-
cant structural destruction, but it produced a side-chain 
clash that could result in backbone shifts in order to avoid 
clashes between amino acid side chains and its local back-Woo HI, et al.  •  Two Korean Cases with MCAD Deficiency
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bone (Fig. 2).
In Patient 2, direct sequencing revealed that the patient 
was a compound heterozygote for 2 known mutations. The 
mutations were a 4-bp deletion at position 449 to 452 in 
exon 6 (p.Thr150ArgfsX4), identical to the mutation in Pa-
tient 1, and a T to A transversion at position 1189 in exon 
11, which resulted in a change from tyrosine to asparagine, 
c.1189T>A (p.Y397N).
DISCUSSION
To identify patients with fatty acid oxidation disorders, 
neonatal screening tests with tandem mass spectrometry, 
including acylcarnitine analysis and confirmatory mutation 
analysis are essential. The high levels of hexanoylcarnitine, 
octanoylcarnitine, and decanoylcarnitine and the octanoyl-
carnitine/decanoylcarnitine ratio can be used to differenti-
ate of MCADD patients from healthy individuals and pa-
tients with other disorders [15]. Urine organic acid analysis 
Mutant allele 1 (Known)
c.449_452delCTGA (p. Thr150ArgfsX4) c.461T>G (p. L154W)





Fig. 1. ACADM mutations detected by sequence 
analysis. Compound heterozygote consisting of a 
known mutation and a novel mutation in Patient 
1. The known maternally-derived allele was a 
4-bp deletion at position 449 to 452 in exon 6, 
altering codon 153 from a proline to a termina-
tion codon (p.Thr150ArgfsX4). The novel mutant 
allele originated from the patient’s father and 
was a T to G transition at position 461 in exon 6, 
resulting in a leucine to tryptophan change at 
codon 154 (p.L154W).
A B
Fig. 2. Diagram of protein structure near the c.461T>G (p.L154W) mutation. (A) Leu154 lies on the loop between the N-terminal α domain and β domain, shown 
in sky blue. (B) The novel Leu154Trp mutation produces side-chain clash with Glu152 (dotted pink line). Hydrogen bonds are shown by the dotted green lines.58     www.kjlm.org
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of MCADD patients revealed peaks of medium-chain di-
carboxylic acids, hexanoylglycine, and suberylglycine. In 
both our patients, significant elevations of medium-chain 
acylcarnitines, especially octanoylcarnitine, were observed, 
and hexanoylglycine and suberylglycine were detected in 
urine organic acid analysis. These findings are typical for 
patients with MCADD.
More than 70 mutations have been identified in the AC­
ADM gene, and the most common type is a missense muta-
tion. The most frequently detected mutation involves an A 
to G transition at nucleotide position 985 (c.985A>G), which 
results in the substitution of glutamate for lysine at amino 
acid position 329 (p.K329E). The distribution of the c.985A> 
G mutation is known to vary according to ethnicity and 
other factors. According to previous publications, a high 
frequency of homozygotes was observed in patients pre-
senting with the clinical symptoms of MCADD, but a rela-
tively lower frequency of homozygotes were found in pa-
tients identified through newborn screening [2, 6, 16]. In 
addition, the frequency of the c.985A>G mutation is much 
higher in Caucasians than in Asians [6, 10, 17, 18]. The c.449_ 
452delCTGA mutation, which was identified in the 2 pa-
tients in the present report, was first reported in 2 of 3 Japa-
nese patients with MCADD in 2005 and also detected in 1 
Korean patient [10, 12]. Prior to this study, the same muta-
tion was detected in 8 of 11 Japanese patients with MCADD 
and 1 Korean patient with MCADD and was not reported 
in Caucasian patients [9-12]. Thus, the allele frequency of 
the c.449_452delCTGA mutation, including the 2 present 
cases, is 46.2% (12/26 alleles), making this mutation the most 
common mutation associated with MCADD in East Asians. 
In the light of the novel mutation presented here and previ-
ous reports on MCADD in East Asians, we expect that the 
distribution of ACADM mutations will vary according to 
ethnic origin.
In the past, there have been several previous reports on 
the genotype-phenotype correlation in MCADD patients. 
The homozygosity of the c.985A>G mutation has been re-
ported to indicate a high level of plasma octanoylcarnitine 
[14, 19] and an increased risk of developing of adverse events 
[20]. However, the pathogenic effects of the majority of mu-
tations in the ACADM gene have not been assessed. A pre-
vious case report described a Japanese patient with the c.449_ 
452delCTGA and c.1189T>A mutations, and these muta-
tions were identical to that of Patient 2 in our present re-
port. In this report, the patient experienced hypoglycemia, 
vomiting, and lethargy that seemed to have triggered due to 
infections after the age of 7 months and was diagnosed with 
the disorder after biochemical tests [11]. Therefore, a close 
follow-up is needed to check for the development of hypo-
glycemia and other symptoms in our patient.
The novel ACADM c.461T>G (p.L154W) mutation was 
not found in 170 healthy subjects. Although leucine at co-
don 154 is not conserved in all species, searches in the evo-
lutionary annotation database (http://jbirc.jbic.or.jp/evola/
search.html) revealed that it is conserved in 12 among 14 
species. All the mutations registered in Human gene muta-
tion database (HGMD, http://www.hgmd.cf.ac.uk/ac/index.
php) are not conserved in all species. In addition, in-silico 
prediction analysis does not perfectly predict all mutations. 
Previous studies reported that scale-invariant feature trans-
form (SIFT) predicted about 70% of substitutions annotated 
as involved in disease as damaging, and about 80% of the 
nonsynonymous SNPs found to affect protein function in 
patients. PolyPhen was also reported to have similar sensi-
tivity [21, 22].
The relationship between genotype and phenotype of the 
c.449_452delCTGA mutation, which was detected in both 
our patients and in other Asian patients, has not been clearly 
defined. A previous report showed slight elevations of plasma 
octanoylcarnitine and/or decanoylcarnitine levels in the 
c.449_452delCTGA mutation carriers among the family 
members of the proband [10]. In the first case of this report, 
octanoylcarnitine level was moderately increased (2.19–2.59 
μmol/L), and this was similar to the octanoylcarnitine level 
observed in infants with a single copy of the c.985A>G 
mutation (1.9–3.2 μmol/L). This was categorized as a severe 
mutation in previous reports [19, 23], and the patient did 
not present any clinical symptoms. Therefore, the novel 
c.461T>G mutation may be associated with a mild pheno-
type. However, we did not measure enzyme activity in our 
patients and did not perform acylcarnitine analysis in either 
of the parents of the first patient. Therefore, the apparent ef-
fect of the novel mutation on enzyme activity and acylcar-
nitine levels could not be assessed. It is also known that en-
vironmental factors, including diet and infections, can limit 
the evaluation of genotype effects. Two contrasting previous 
reports described one patient who had a homozygous frame-
shift mutation with no residual MCAD enzyme activity, but 
showed no severe clinical manifestations for several months 
after birth, and another compound heterozygote patient 
who had c.985A>G and another missense mutation and 
died unexpectedly a few days after birth [2, 3, 24]. There-
fore, further data accumulation through clinical, biochemi-
cal, and molecular approaches is needed to evaluate the re-
lationship between clinical phenotype and genotype.
In summary, we have described 2 Korean pediatric pa-
tients with MCADD that was diagnosed by molecular stud-Woo HI, et al.  •  Two Korean Cases with MCAD Deficiency
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ies; 1 of the cases showed a novel mutation, c.461T>G, in 
the ACADM gene. We conclude that c.449_452delCTGA is 
a common mutation in Korean MCADD patients. We be-
lieve that this report will contribute to a better understand-
ing of the genetic background in Asian MCADD patients. 
The detection of novel mutations and further molecular 
and biochemical studies are needed to establish genotype-
phenotype correlations of MCADD and to manage the dis-
ease at an early stage.
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